Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tyra Biosciences, Inc. (TYRA : NSDQ)

• Company Description    Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif. Number of Employees: 25

• Price / Volume Information    Yesterday's Closing Price: $9.46 Daily Weekly Monthly 20 Day Moving Average: 61,198 shares Shares Outstanding: 41.76 (millions) Market Capitalization: $395.06 (millions) Beta: 52 Week High: $31.36 52 Week Low: $6.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 11.95% 22.58% 12 Week -21.10% -11.33% Year To Date -32.76% -17.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2656 STATE STREET - CARLSBAD,CA 92008 USA ph: 619-728-4760 fax: - aconrad@tyra.bio http://www.tyra.bio

• General Corporate Information    Officers Todd Harris - Chief Executive Officer and President Esther van den Boom - Chief Financial Officer Gilla Kaplan - Director Nina Kjellson - Director Robert More - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90240B106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 41.76 Most Recent Split Date: (:1) Beta: Market Capitalization: $395.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.32 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 14.71% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.35 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -50.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - 59.99 12/31/21 - 84.09 09/30/21 - 65.75 Quick Ratio 03/31/22 - 59.99 12/31/21 - 84.09 09/30/21 - 65.75 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 7.00 12/31/21 - 7.31 09/30/21 - 7.57 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©